J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity

Johnson & Johnson’s reported sales rose 5.2% during Q3, though its earnings declined significantly due to its ongoing M&A activity.

The pharma giant released its latest earnings report Thursday morning, highlighted by $22.4 billion in quarterly sales. J&J experienced operational sales growth of 6.3% and adjusted operational growth of 5.4%.